 - Patients with advanced AML or ALL defined as beyond first remission, primary refractory disease, or evolved from myelodysplastic or myeloproliferative syndromes; or patients with MDS expressed as refractory anemia with excess blasts RAEB, refractory cytopenia with multilineage dysplasia RCMD, RCMD with ringed sideroblasts RCMD-RS, or chronic myelomonocytic leukemia CMML 